Effects of exogenous melatonin on sleep and circadian rhythms in women with premenstrual dysphoric disorder.
body temperature
circadian rhythm
melatonin
menstrual cycle
mood
premenstrual dysphoric disorder
sleep
Journal
Sleep
ISSN: 1550-9109
Titre abrégé: Sleep
Pays: United States
ID NLM: 7809084
Informations de publication
Date de publication:
10 12 2021
10 12 2021
Historique:
received:
07
02
2021
revised:
01
07
2021
pubmed:
10
7
2021
medline:
18
3
2022
entrez:
9
7
2021
Statut:
ppublish
Résumé
We previously found normal polysomnographic (PSG) sleep efficiency, increased slow-wave sleep (SWS), and a blunted melatonin secretion in women with premenstrual dysphoric disorder (PMDD) compared to controls. Here, we investigated the effects of exogenous melatonin in five patients previously studied. They took 2 mg of slow-release melatonin 1 h before bedtime during their luteal phase (LP) for three menstrual cycles. At baseline, patients spent every third night throughout one menstrual cycle sleeping in the laboratory. Measures included morning urinary 6-sulfatoxymelatonin (aMt6), PSG sleep, nocturnal core body temperature (CBT), visual analog scale for mood (VAS-Mood), Prospective Record of the Impact and Severity of Menstrual Symptoms (PRISM), and ovarian plasma hormones. Participants also underwent two 24-hour intensive physiological monitoring (during the follicular phase and LP) in time-isolation/constant conditions to determine 24-hour plasma melatonin and CBT rhythms. The same measures were repeated during their third menstrual cycle of melatonin administration. In the intervention condition compared to baseline, we found increased urinary aMt6 (p < 0.001), reduced objective sleep onset latency (p = 0.01), reduced SWS (p < 0.001), and increased Stage 2 sleep (p < 0.001). Increased urinary aMt6 was correlated with reduced SWS (r = -0.51, p < 0.001). Circadian parameters derived from 24-hour plasma melatonin and CBT did not differ between conditions, except for an increased melatonin mesor in the intervention condition (p = 0.01). Ovarian hormones were comparable between the conditions (p ≥ 0.28). Symptoms improved in the intervention condition, as measured by the VAS-Mood (p = 0.02) and the PRISM (p < 0.001). These findings support a role for disturbed melatonergic system in PMDD that can be partially corrected by exogenous melatonin.
Identifiants
pubmed: 34240212
pii: 6317701
doi: 10.1093/sleep/zsab171
pmc: PMC8664575
pii:
doi:
Substances chimiques
Melatonin
JL5DK93RCL
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : CIHR
ID : MOP-38064
Pays : Canada
Informations de copyright
© Sleep Research Society 2021. Published by Oxford University Press on behalf of the Sleep Research Society. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
PLoS One. 2013 May 17;8(5):e63773
pubmed: 23691095
Int J Neurosci. 1985 Apr;26(1-2):9-13
pubmed: 2581912
Arch Womens Ment Health. 2013 Aug;16(4):279-91
pubmed: 23624686
Pflugers Arch. 2001 Aug;442(5):729-37
pubmed: 11512029
J Psychosom Obstet Gynaecol. 2000 Dec;21(4):205-11
pubmed: 11191167
J Biol Rhythms. 1997 Dec;12(6):509-17
pubmed: 9406024
Am J Obstet Gynecol. 2009 Aug;201(2):139.e1-8
pubmed: 19398092
Sleep. 2008 Mar;31(3):383-93
pubmed: 18363315
Eur Neuropsychopharmacol. 2007 Jan 15;17(2):108-15
pubmed: 16574382
Nature. 1975 Nov 6;258(5530):80
pubmed: 1186885
Biochem Pharmacol. 2004 Jun 1;67(11):2023-30
pubmed: 15135299
Aging (Albany NY). 2019 Oct 16;11(20):9013-9024
pubmed: 31619582
Biol Psychiatry. 1999 Feb 1;45(3):313-20
pubmed: 10023508
Eur Neuropsychopharmacol. 2014 Nov;24(11):1719-28
pubmed: 25224106
Prim Care Companion J Clin Psychiatry. 2005;7(2):53-60
pubmed: 15841196
Br J Pharmacol. 2018 Aug;175(16):3200-3208
pubmed: 29512136
J Psychopharmacol. 2019 Aug;33(8):923-947
pubmed: 31271339
Psychiatry Res. 1999 Jun 30;86(3):185-92
pubmed: 10482337
J Psychopharmacol. 2015 Jul;29(7):764-76
pubmed: 25922426
Hum Brain Mapp. 2020 Jun 15;41(9):2281-2291
pubmed: 32125068
Am J Psychiatry. 2021 Mar 1;178(3):256-265
pubmed: 33297719
Horm Behav. 2020 Aug;124:104782
pubmed: 32470339
Science. 1974 Jun 28;184(4144):1341-8
pubmed: 4151465
Am J Psychiatry. 1995 Mar;152(3):404-12
pubmed: 7864267
PLoS One. 2012;7(12):e51929
pubmed: 23284821
Am J Psychiatry. 1987 Jun;144(6):808-10
pubmed: 3592005
Sleep. 2012 Oct 01;35(10):1395-402
pubmed: 23024438
Sleep. 2010 May;33(5):647-56
pubmed: 20469807
Neuron. 2003 Feb 20;37(4):563-76
pubmed: 12597855
J Biol Rhythms. 2002 Feb;17(1):4-13
pubmed: 11837947
Sleep Med. 2012 Sep;13(8):1071-8
pubmed: 22749440
J Neurotrauma. 2020 Dec 15;37(24):2647-2655
pubmed: 32772826
Psychoneuroendocrinology. 2017 Feb;76:135-143
pubmed: 27923181
J Neuroendocrinol. 1995 Dec;7(12):949-56
pubmed: 8745273
Curr Opin Psychol. 2020 Aug;34:43-49
pubmed: 31610482
CNS Drugs. 2001;15(4):277-85
pubmed: 11463133
FASEB J. 2004 Nov;18(14):1646-56
pubmed: 15522910
J Pineal Res. 2019 Aug;67(1):e12575
pubmed: 30937953
Chronobiol Int. 2012 May;29(4):415-29
pubmed: 22489607
Front Neuroendocrinol. 2020 Apr;57:100838
pubmed: 32268180
Compr Physiol. 2016 Jun 13;6(3):1135-60
pubmed: 27347888
J Pineal Res. 2006 Mar;40(2):116-24
pubmed: 16441548
J Biol Rhythms. 1997 Oct;12(5):443-56
pubmed: 9376643
Med Hypotheses. 2007;69(1):120-4
pubmed: 17197111
J Biol Rhythms. 1997 Feb;12(1):34-46
pubmed: 9104689
J Pharmacol Exp Ther. 2003 Mar;304(3):931-9
pubmed: 12604667
Int J Neuroprot Neuroregener. 2006;2:185-9
pubmed: 18389085
J Pineal Res. 2019 Apr;66(3):e12544
pubmed: 30586215
Front Endocrinol (Lausanne). 2019 Mar 01;10:87
pubmed: 30881340
Am J Psychiatry. 1991 Oct;148(10):1329-35
pubmed: 1897612
Sleep. 1997 Feb;20(2):124-31
pubmed: 9143072
Endocrine. 2005 Jul;27(2):101-10
pubmed: 16217123
N Engl J Med. 1997 Apr 3;336(14):1028-9
pubmed: 9091795
Am J Psychiatry. 1993 Sep;150(9):1417-9
pubmed: 8352356
Br J Psychiatry. 2007 Apr;190:287-92
pubmed: 17401033
J Physiol. 2004 Nov 15;561(Pt 1):339-51
pubmed: 15459246
Arch Gen Psychiatry. 2012 Mar;69(3):300-5
pubmed: 22393222
Proc Natl Acad Sci U S A. 1918 Dec;4(12):370-3
pubmed: 16576330
Am J Obstet Gynecol. 2005 Aug;193(2):352-60
pubmed: 16098854
Transl Psychiatry. 2017 Aug 8;7(8):e1193
pubmed: 28786978
Menopause Int. 2012 Jun;18(2):73-6
pubmed: 22611226
Chronobiol Int. 2011 May;28(5):415-24
pubmed: 21721857
Psychosom Med. 2004 Sep-Oct;66(5):707-13
pubmed: 15385695
Neuropsychopharmacology. 2001 Nov;25(5 Suppl):S102-8
pubmed: 11682284
Psychiatry Res. 1999 Feb 22;85(2):127-43
pubmed: 10220004
Front Endocrinol (Lausanne). 2020 Mar 06;11:85
pubmed: 32210911
Theor Biol Med Model. 2014 Apr 11;11:16
pubmed: 24725531
J Affect Disord. 2013 Jun;148(2-3):357-67
pubmed: 23357659
Int J Chronobiol. 1976;4(2):97-110
pubmed: 1027738
Brain Imaging Behav. 2019 Jun;13(3):717-724
pubmed: 29774500
Int J Endocrinol. 2010;2010:259345
pubmed: 20145718
J Clin Endocrinol Metab. 1996 Feb;81(2):728-35
pubmed: 8636295
Brain Struct Funct. 2017 Sep;222(7):2921-2939
pubmed: 28478550
Sleep Med. 2007 Dec;8 Suppl 3:34-42
pubmed: 18032103
Front Neuroendocrinol. 2020 Oct;59:100856
pubmed: 32730861
J Affect Disord. 1999 Jun;53(3):269-73
pubmed: 10404713
J Physiol. 2008 Jan 15;586(2):639-47
pubmed: 18006583
J Biol Rhythms. 1997 Feb;12(1):47-64
pubmed: 9104690
J Reprod Fertil. 1986 Nov;78(2):711-7
pubmed: 3806524
J Sleep Res. 2012 Oct;21(5):535-45
pubmed: 22417163
J Pineal Res. 2001 Jan;30(1):34-42
pubmed: 11168905
Chronobiol Int. 2002 Jul;19(4):721-30
pubmed: 12182499
Cochrane Database Syst Rev. 2013 Jun 07;(6):CD001396
pubmed: 23744611
CNS Drugs. 2019 Dec;33(12):1167-1186
pubmed: 31722088
Physiol Rep. 2020 Jan;8(2):e14353
pubmed: 31981319
J Clin Endocrinol Metab. 2001 Oct;86(10):4789-97
pubmed: 11600542
J Appl Physiol (1985). 1996 Jan;80(1):25-9
pubmed: 8847311
N Engl J Med. 1995 Jun 8;332(23):1574-5
pubmed: 7739713
Am J Psychiatry. 1989 Sep;146(9):1215-7
pubmed: 2764181
J Affect Disord. 2018 Mar 15;229:239-246
pubmed: 29329055